Last reviewed · How we verify
NCT03283852: FORDEV
Identifying New Genetic Causes to Development Disorders
trial testing blood sample in Disorders of Sex Development in 1,100 participants. Currently enrolling.
21 February 2027
Quick facts
| Lead sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,100 |
| Start date | 21 February 2017 |
| Primary completion | 21 February 2027 |
| Estimated completion | 21 February 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- blood sample — full drug profile →
Conditions studied
- Disorders of Sex Development — all drugs for Disorders of Sex Development →
- Growth Disorders — all drugs for Growth Disorders →
- Puberty Disorders — all drugs for Puberty Disorders →
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild — full company profile →
Who can join
Eligibility, any sex, with Disorders of Sex Development or Growth Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Disorders of growth, puberty and sex development can have genetic causes. The exome analysis could detect new mutations responsible for these disorders and the frequency of these mutations in these disorders, their association with other malformations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03283852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sample
Trials testing the same drug.
- NCT07370792 — Contribution of Optical Genome Mapping (OGM) in the Diagnosis of Multiple Congenital Malformations With or Without Intel · NA · recruiting
- NCT07273331 — Nursing Needs of Patients With Cirrhosis · enrolling by invitation
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06968598 — Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models · NA · not yet recruiting
- NCT07332702 — Long Read Analysis in Spinal Muscular Atrophy - LOREASI · NA · recruiting
Other recruiting trials for Disorders of Sex Development
Currently open trials in the same condition.
- NCT04463316 — GROWing Up With Rare GENEtic Syndromes · recruiting
- NCT06692049 — Gonadal Tissue Cryopreservation for Fertility Preservation in Children with a Disorder of Sex Development · recruiting
Other Fondation Ophtalmologique Adolphe de Rothschild trials
Trials by the same sponsor.
- NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
- NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
- NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
- NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
- NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03283852 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
- Last refreshed: 5 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03283852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing